Intech Investment Management LLC Has $75,000 Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)

Intech Investment Management LLC lifted its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) by 218.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 51,924 shares of the company’s stock after purchasing an additional 35,632 shares during the quarter. Intech Investment Management LLC’s holdings in Compass Therapeutics were worth $75,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. The Manufacturers Life Insurance Company acquired a new position in Compass Therapeutics during the third quarter worth $79,000. XTX Topco Ltd bought a new stake in shares of Compass Therapeutics during the third quarter worth about $37,000. Barclays PLC raised its holdings in shares of Compass Therapeutics by 195.4% in the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after acquiring an additional 112,614 shares during the last quarter. Geode Capital Management LLC lifted its position in Compass Therapeutics by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after acquiring an additional 19,095 shares in the last quarter. Finally, SG Americas Securities LLC increased its holdings in Compass Therapeutics by 921.6% during the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after purchasing an additional 356,352 shares in the last quarter. 68.43% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on CMPX shares. Guggenheim began coverage on Compass Therapeutics in a report on Monday, February 24th. They issued a “buy” rating and a $12.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Piper Sandler started coverage on shares of Compass Therapeutics in a research note on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 target price for the company. D. Boral Capital reissued a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research report on Tuesday, February 25th. Finally, Jefferies Financial Group upped their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, February 10th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.38.

Compass Therapeutics Stock Down 5.2 %

Compass Therapeutics stock opened at $1.99 on Friday. The firm has a 50 day moving average price of $2.85 and a 200-day moving average price of $2.09. Compass Therapeutics, Inc. has a twelve month low of $0.77 and a twelve month high of $4.08. The company has a market capitalization of $275.18 million, a P/E ratio of -5.38 and a beta of 1.19.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Equities analysts expect that Compass Therapeutics, Inc. will post -0.36 EPS for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.